Eureka Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
5858 Horton St Ste 362, Emeryville, Cali...Phone Number
(510) 654-7045Website
www.eurekatherapeutics.comRevenue
$40 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Eureka Therapeutics
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative technology platforms to target cancer-specific treatments, particularly for solid tumors and other malignancies. Their proprietary platforms, E-ALPHA and ARTEMIS, leverage high-throughput screening and T cell therapy to create potential treatment options. The company aims to enhance cancer treatment through a deeper understanding of various cancer types and the application of advanced technologies. Their intended clients include patients suffering from different forms of cancer, as well as healthcare professionals involved in cancer treatment.Explore more
Eureka Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eureka Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Eureka Therapeutics recently announced quarterly report
Click to see if Eureka Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Eureka Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Eureka Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Eureka Therapeutics has new funding data
Check out if Eureka Therapeutics is spiking on competitors!
Product Launch: Get notified when Eureka Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Eureka Therapeutics
Recommended Actions
Find VP level buyers at Eureka Therapeutics
Find 2 more new buyers
Compare Similar Companies to Eureka Therapeutics
Compare insights from companies similar to Eureka Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eureka Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eureka Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eureka Therapeutics.
Eureka Therapeutics financials insights
Gather financial insights about Eureka Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Series A
$1.2M
2008
Series B
$6M
2014
Series C
$21M
2018
Series D
$60M
2020
Series E
$45M
Eureka Therapeutics Tech Stack
A closer look at the technologies used by Eureka Therapeutics
Most Recent Scoops
Person-Based
Project
Spending/Investment
Project
, according to a mid-level source in Financial Planning, has completed initiatives related to accounts payable within the last nine months.
Accounting, Financial Planning, Billing & Invoice, Finance, Financial Strategy
Project
, according to a mid-level source in Financial Planning, has completed initiatives related to enterprise resource planning (ERP) software within the last nine months.
Financial Planning, Enterprise Software, Software, Enterprise Resource Planning, Finance, Financial Strategy
Project
Cloud, Accounting, Financial Planning, Financial Systems, Software, Financial Reporting, Finance, Financial Strategy
Eureka Therapeutics News & Media
Eureka Therapeutics Announces UCSF Benioff Children’s Hospitals as First California Site for ARYA-2 Clinical Trial Targeting Pediatric Liver Cancers
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial (NCT04634357). The ARYA-2 trial is evaluating Eureka’s investigational ARTEMIS® ET140203 T-cell therapy which targets the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex. This therapy is designed to treat pediatricEureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Tcelltherapy--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced the advancement of its ARYA-3 clinical trial to Phase II (NCT04864054). This milestone represents one of the first engineered T-cell programs targeting solid tumors to reach Phase II. The ARYA-3 trial is evaluating Eureka’s investigational ARTEMIS® ECT204 T-cell therapy in adult patients with GPC3-positive advancEureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS® T-Cell Therapy in Pediatric Liver Cancer
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced that the California Institute for Regenerative Medicine (CIRM) awarded the Company a $10.6 million grant to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of pediatric patients with refractory/relapsed liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS),Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS® T-cell receptor platform. MSLN is a cell-surface protein overexpressed in many s
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Eureka Therapeutics
Sign Up For FreeTo access detailed company insights
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative technology platforms to target cancer-specific treatments, particularly for solid tumors and other malignancies. Their proprietary platforms, E-ALPHA and ARTEMIS, leverage high-throughput screening and T cell therapy to create potential treatmen... Read More
